To manufacture and commercialise baricitinib in India, approved for use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalised adults
The latest therapy with links to the city is the glucose molecule 2-DG and its anti-Covid-19 therapeutic application that was given a green signal by Indian drug regulatory authorities
The drug has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of Defence Research and Development Organisation (DRDO).
Hyderabad-based Dr Reddy’s Laboratories has collaborated with RDIF to import the first consignment of Sputnik-V while it is expected that the pharma giant will start manufacturing from its local facilities in India
As part of the review process, the drug major will present the safety profile of phase 2 study, and interim data of phase 3 trial, which is expected to be complete by February 21